Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies Meeting Abstract
| Authors: | Hong, D. S.; Schoffski, P.; Calvo, A.; Sarantopoulos, J.; De Olza, M. O.; Carvajal, R. D.; Prawira, A.; Kyi, C.; Esaki, T.; Akerley, W. L.; De Braud, F. G.; Hui, R.; Zhang, T.; Soo, R. A.; Maur, M.; Weickhardt, A. J.; Chowdhury, N. R.; Sabatos-Peyton, C.; Kwak, E. L.; Tan, D. S. W. |
| Abstract Title: | Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 140s |
| Language: | English |
| ACCESSION: | WOS:000442916001386 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.3012 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3012 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
